Structure-based identification of compounds with potential as selective BLT1 antagonists.

ABSTRACT: The pro-inflammatory molecule leukotriene B4 binds to the leukotriene B4 receptors 1 and 2 (BLT1 and BLT2). Although BLT1 has potential as a target for treating inflammatory diseases, no selective BLT1 antagonist has been marketed to date. Most of the developed compounds bind to both BLT receptors, which are now considered to have some opposite functions. Our goal was to identify potential selective antagonists of BLT1 that could be advanced in future studies for the treatment of inflammatory conditions. We performed a robust virtual screening process using a library of bioactive compounds. The library was screened against BLT1 first, and the top hits were then screened against BLT2. The top eight candidates were selected based on several criteria for further studies, starting with predict

SUBMITTER: Alkhodier RA 

PROVIDER: S-EPMC12799605 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature